Testing for genetic risk factors may improve myeloma treatments by identifying those at risk for more aggressive disease. This study, published in the Journal of Clinicial Oncology and led by researchers in London, including our own Myeloma Institute Director, Dr. Gareth Morgan, is the first to link genetic mutations in myeloma cells to the chances of surviving the disease.
Genetic Mutation Analysis May Improve Treatment in Multiple Myeloma
- UAMS Study Identifies One Reason Myeloma Patients Respond Differently to Treatment
- Myeloma Patient’s Loved Ones Roll ‘Ride for Research’ in Her Honor
- UAMS Myeloma Institute Team Goes the Distance to Fight Cancer
- Conway Cyclist Joins UAMS Myeloma Institute Team to Honor Dad
- Myeloma Institute Hosts Patient Power Event on Rare Blood Diseases